Stockscreener 앱 받기
433.34
0.15%
0.65
전일 마감가:
$432.69
열려 있는:
$432.23
하루 거래량:
506.45K
Relative Volume:
0.67
시가총액:
$19.55B
수익:
$3.08B
순이익/손실:
$1.24B
주가수익비율:
16.92
EPS:
25.6108
순현금흐름:
$1.07B
1주 성능:
-1.51%
1개월 성능:
+7.35%
6개월 성능:
+52.19%
1년 성능:
+16.24%
1일 변동 폭
$428.04
$435.38
1주일 범위
$427.86
$443.11
52주 변동 폭
$266.98
$459.48
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
433.34 | 19.57B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
144.06 | 63.49B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.04 | 43.84B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.48 | 40.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.31 | 22.52B | 16.70B | -157.13M | 1.19B | -0.1446 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Artificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034 - GlobeNewswire Inc.
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case - Insider Monkey
PH-ILD hospitalization data on inhaled treprostinil — United Therapeutics at CHEST 2025 - Stock Titan
Callan Family Office LLC Increases Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Inspire Investing LLC Trims Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp. Hits New 52-Week High of $455.26 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $459.48 - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High of $455.00 - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Sets New 52-Week HighHere's What Happened - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat
QRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
Polaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHR - MarketBeat
Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR - MarketBeat
A Look at United Therapeutics (UTHR) Valuation as Tyvaso Shows Breakthrough Results in Late-Stage IPF Trial - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Robeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
United Therapeutics rides Tyvaso optimism as IPF trial gains momentum - S&P Global
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics COO sells $9.49m in UTHR stock - Investing.com India
Is IPF the Next Big Market Opportunity for United Therapeutics? - Yahoo Finance
UBS maintains United Therapeutics stock Buy rating amid patent litigation - Investing.com India
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics stock price target raised to $580 by UBS on Tyvaso outlook - Investing.com Australia
United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments - Investing.com Australia
United Therapeutics (UTHR): UBS Raises Price Target to $580, Mai - GuruFocus
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments By Investing.com - Investing.com Australia
Will United Therapeutics Corporation (UTH) stock beat international competitionWeekly Trade Review & Reliable Trade Execution Plans - newser.com
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data - Investing.com Canada
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data By Investing.com - Investing.com South Africa
United Therapeutics Corporation $UTHR Holdings Lifted by State of Alaska Department of Revenue - MarketBeat
Why United Therapeutics Corporation (UTH) stock stays undervaluedTrade Ideas & Verified Chart Pattern Trade Signals - newser.com
Analyzing drawdowns of United Therapeutics Corporation with statistical tools2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Chart based analysis of United Therapeutics Corporation trendsInsider Selling & Real-Time Stock Movement Alerts - newser.com
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.63%
1.87%
자본화:
|
볼륨(24시간):